Cephalon, Inc. (298-116)

Tufano, Peter (1998) Cephalon, Inc. (298-116). [Case]

Abstract

In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to finance its development). The firm's CFO is considering a variety of financing strategies, including buying call options on the firm's own stock and paying for those options by issuing shares at the current time.

Item Type: Case
Keywords: finance, accounting, financial management
Subject(s): Finance
Date Deposited: 01 Apr 2016 13:45
Last Modified: 01 Apr 2016 13:45
Funders: n/a
URI: http://eureka.sbs.ox.ac.uk/id/eprint/6028

Actions (login required)

Edit View Edit View